{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T14:17:26Z","timestamp":1772979446458,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Real-world data on patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) remain scarce. In this descriptive observational retrospective cohort study, we describe characteristics, treatments, and real-world progression-free survival (rwPFS) and overall survival (OS) among patients with ROS1-positive advanced NSCLC (de novo or recurrent) using secondary data pooled from clinical sites in Canada, France, Germany, Portugal, and Spain as part of the Oncology Evidence Network. Site-specific patient inclusion periods occurred between 2009 and 2023, with follow-up to 2024, allowing \u22651 year of potential follow-up at each site. In total, 108 patients were included, with most (n = 105; 97.2%) having a de novo diagnosis of advanced NSCLC. 103 patients (95.4%) received \u22651 line of systemic anticancer therapy (SACT), of which 65 (63.1%) received first-line targeted therapy, mostly crizotinib monotherapy (n = 45) or crizotinib-based regimens (n = 10), with a median (95% CI) rwPFS and OS of 14.0 (8.3\u201319.8) and 47.9 (27.3\u2013not estimable) months, respectively. Thirty-eight of the 103 SACT-treated patients (36.9%) received first-line non-targeted therapy, mostly platinum-based chemotherapy (n = 26); median (95% CI) rwPFS and OS were 9.0 (7.5\u201311.0) and 29.3 (17.7\u201365.7) months, respectively. Results from this study indicated a tendency for longer survival using currently available ROS1-targeted versus non-targeted therapy for patients with ROS1-positive advanced NSCLC. Nevertheless, survival outcomes were limited, highlighting the importance of more effective emerging treatments for ROS1-positive disease.<\/jats:p>","DOI":"10.3390\/curroncol33030152","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:05:44Z","timestamp":1772795144000},"page":"152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe"],"prefix":"10.3390","volume":"33","author":[{"given":"Winson Y.","family":"Cheung","sequence":"first","affiliation":[{"name":"Oncology Outcomes, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-1296","authenticated-orcid":false,"given":"Adam","family":"Lee","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Oncology, Bristol Myers Squibb, Uxbridge UB8 1DH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Bote de Cabo","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Burdenski","sequence":"additional","affiliation":[{"name":"University Cancer Center Frankfurt (UCT), 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[{"name":"Thoraxklinik at Heidelberg University Hospital and Translational Lung Research Center Member of the German Center for Lung Research, 69126 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9161-5937","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Pinto-Correia","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., Porto Salvo, 2740-266 Oeiras, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Deshayes","sequence":"additional","affiliation":[{"name":"Center Hospitalier Universitaire de Caen, 14000 Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut du Thorax Curie-Montsouris, Institut Curie, 75248 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Hindocha","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., London W2 1AF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ine","family":"Madden","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., London W2 1AF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9858-0120","authenticated-orcid":false,"given":"Marta","family":"Mella","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., 20124 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Moreira","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., Porto Salvo, 2740-266 Oeiras, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-2361","authenticated-orcid":false,"given":"Silvia","family":"Rizzi","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delvys Rodr\u00edguez","family":"Abreu","sequence":"additional","affiliation":[{"name":"Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-3673","authenticated-orcid":false,"given":"Marta","family":"Soares","sequence":"additional","affiliation":[{"name":"Portuguese Oncology Institute of Porto (IPO-Porto), 4200-162 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Thomas","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., London W2 1AF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Han","sequence":"additional","affiliation":[{"name":"Vivantes Klinikum in Friedrichshain, 10249 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-2176","authenticated-orcid":false,"given":"Christophe Y.","family":"Calvet","sequence":"additional","affiliation":[{"name":"Global Medical, Bristol Myers Squibb, Princeton, NJ 08540, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Emanuel","sequence":"additional","affiliation":[{"name":"Real World Data Analytics, Bristol Myers Squibb, Uxbridge UB8 1DH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrudula B.","family":"Glassberg","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Bristol Myers Squibb, Madison, NJ 07940, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazel","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Syneos Health, Farnborough GU14 7BF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Rault","sequence":"additional","affiliation":[{"name":"Data Gnosis, 35000 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08540, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil, 40 Avenue de Verdun, 94000 Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_4","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.8.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"ref_5","first-page":"300","article-title":"Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: A meta-analysis","volume":"4","author":"Zhu","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fois, S.S., Paliogiannis, P., Zinellu, A., Fois, A.G., Cossu, A., and Palmieri, G. (2021). Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020612"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","article-title":"Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)","volume":"152","author":"Griesinger","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jclinpath-2020-207280","article-title":"Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)","volume":"75","author":"Salas","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Provencio, M., Cobo, M., Rodriguez-Abreu, D., Calvo, V., Carcereny, E., Cantero, A., Bernabe, R., Benitez, G., Castro, R.L., and Massuti, B. (2022). Determination of essential biomarkers in lung cancer: A real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09830-8"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Terrenato, I., Ercolani, C., Di Benedetto, A., Gallo, E., Melucci, E., Casini, B., Rollo, F., Palange, A., Visca, P., and Pescarmona, E. (2022). A real-world systematic analysis of driver mutations\u2019 prevalence in early- and advanced-stage NSCLC: Implications for targeted therapies in the adjuvant setting. Cancers, 14.","DOI":"10.3390\/cancers14122971"},{"key":"ref_11","unstructured":"(2025, June 02). XALKORI\u00ae (Crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xalkori_crizotinib_approved_by_u_s_fda_for_the_treatment_of_patients_with_ros1_positive_metastatic_non_small_cell_lung_cancer."},{"key":"ref_12","unstructured":"(2025, June 02). XALKORI\u00ae (Crizotinib) Receives Approval in European Union for the Treatment of Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xalkori_crizotinib_receives_approval_in_european_union_for_the_treatment_of_patients_with_ros1_positive_advanced_non_small_cell_lung_cancer#:~:text=The%20European%20Commission\u2019s%20approval%20of,Phase%201%20study%20(Study%201001)."},{"key":"ref_13","unstructured":"Health Canada (2025, June 02). Drug and Health Product Portal: Regulatory Decision Summary for Xalkori, Available online: https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00285."},{"key":"ref_14","unstructured":"(2025, June 02). FDA Approves Roche\u2019s RozlytrekTM (Entrectinib) for People with ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumours. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2019-08-16."},{"key":"ref_15","unstructured":"Hoffmann-La Roche Limited (Roche Canada) (2025, May 16). Health Canada Grants Market Authorization to ROZLYTREK\u00ae (Entrectinib) for ROS1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients, not Previously Treated with Crizotinib. Available online: https:\/\/www.newswire.ca\/news-releases\/health-canada-grants-market-authorization-to-rozlytrek-r-entrectinib-for-ros1-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-patients-not-previously-treated-with-crizotinib-1--845499128.html#:~:text=MISSISSAUGA%2C%20ON%2C%20May%2020%2C,cancer%20(NSCLC)%2C%20not%20previously."},{"key":"ref_16","unstructured":"(2025, June 02). CHMP Recommends EU Approval of Roche\u2019s Rozlytrek for People with NTRK Fusion-Positive Solid Tumours and for People with ROS1-Positive, Advanced Non-Small Cell Lung Cancer. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2020-05-29b."},{"key":"ref_17","unstructured":"Bristol Myers Squibb (2025, June 05). U.S. Food and Drug Administration Approves Augtyro\u2122 (Repotrectinib), A Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC). Available online: https:\/\/news.bms.com\/news\/details\/2023\/US-Food-and-Drug-Administration-Approves-Augtyro\/default.aspx."},{"key":"ref_18","unstructured":"European Medicines Agency (2025, June 05). Augtyro (Repotrectinib): An Overview of Augtyro and Why It Is Authorised in the EU, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/augtyro-epar-medicine-overview_en.pdf."},{"key":"ref_19","unstructured":"Bristol-Myers Squibb Canada (2025, June 05). Product Monograph-AUGTYROTM Repotrectinib Capsules. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00080483.PDF."},{"key":"ref_20","unstructured":"US Food and Drug Administration (2025, October 06). FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1200\/JCO-24-02133","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2024.2","volume":"42","author":"Bazhenova","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_23","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2025, May 16). Transparency Committee Summary: Crizotinib. Available online: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-01\/xalkori_ros1_13052020_summary_ct18042.pdf."},{"key":"ref_24","unstructured":"Servi\u00e7o Nacional de Sa\u00fade (2025, May 16). Relat\u00f3rio P\u00fablico de Avalia\u00e7\u00e3o: XALKORI (Crizotinib). Available online: https:\/\/www.infarmed.pt\/documents\/15786\/3368817\/Relat%C3%B3rio+de+avalia%C3%A7%C3%A3o+de+financiamento+p%C3%BAblico+de+Xalkori+%28crizotinib%29\/74be132b-4050-43dc-eab2-58ab2c583e90?version=1.0."},{"key":"ref_25","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2025, May 16). Transparency Committee Summary: Entrectinib. Available online: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-02\/rozlytrek_210721_summary_ct19238.pdf."},{"key":"ref_26","unstructured":"Servi\u00e7o Nacional de Sa\u00fade (2025, May 16). Relat\u00f3rio P\u00fablico de Avalia\u00e7\u00e3o: ROZLYTREK (Entrectinib). Available online: https:\/\/www.infarmed.pt\/documents\/15786\/3368817\/Relat%C3%B3rio+de+avalia%C3%A7%C3%A3o+de+financiamento+p%C3%BAblico+de+Rozlytrek+%28entrectinib%29+2\/80ddcbb4-f3b5-8c25-1d3c-b905ac1af6de?version=1.0."},{"key":"ref_27","unstructured":"pan-Canadian Oncology Drug Review (pCODR) (2025, May 14). pCODR Expert Review Committee (pERC): Final Recommendation (Crizotinib [Xalkori] as a Single Agent as First-Line Treatment for Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer [NSCLC]). Available online: https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10151CrizotinibNSCLC_fnRec_EC_approvedbyChair_Post_23May2019_final_cleaned.pdf."},{"key":"ref_28","unstructured":"pan-Canadian Oncology Drug Review (pCODR) (2025, February 14). pCODR Expert Review Committee (pERC): Final Recommendation (Entrectinib [Rozlytrek] as Monotherapy for the First-Line Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer). Available online: https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10206EntrectinibROS1NSCLC_FnRec_EarlyConv_ApprovedbyChair_EC27Jan2021_final.pdf."},{"key":"ref_29","unstructured":"pan-Canadian Oncology Drug Review (pCODR) (2025, February 14). Provincial Funding Summary: Crizotinib (Xalkori) for ROS1-Positive Advanced Non-Small Cell Lung Cancer (pCODR 10151). Available online: https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/pcodr-provfund-10151-crizotinib-xalkori-ROS-positive.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/curroncol29030160","article-title":"Real-world management and outcomes of crizotinib-treated ROS1-rearranged NSCLC: A retrospective Canadian cohort","volume":"29","author":"Gibson","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11523-021-00860-z","article-title":"Real-world outcomes among crizotinib-treated patients with ROS1-positive advanced non-small-cell lung cancer: A community oncology-based observational study","volume":"17","author":"Waterhouse","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107253","DOI":"10.1016\/j.lungcan.2023.107253","article-title":"Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands","volume":"181","author":"Damhuis","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2217\/fon-2021-1102","article-title":"Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol."},{"key":"ref_34","first-page":"100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2217\/fon-2019-0025","article-title":"I-O Optimise: A novel multinational real-world research platform in thoracic malignancies","volume":"15","author":"Ekman","year":"2019","journal-title":"Future Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14796694.2025.2466416","article-title":"Advancing real-world research in thoracic malignancies: Learnings from the international I-O Optimise initiative","volume":"21","author":"Johnsen","year":"2025","journal-title":"Future Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e13554","DOI":"10.1200\/JCO.2021.39.15_suppl.e13554","article-title":"OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling\u2014The use of a common data model and shared analytical methods","volume":"39","author":"Levick","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort","volume":"33","author":"Mazieres","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice","volume":"13","author":"Park","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.21037\/jtd.2019.07.44","article-title":"Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: A retrospective analysis","volume":"11","author":"Masuda","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/j.cllc.2020.03.008","article-title":"Treatment patterns and clinical outcomes among patients with ROS1-rearranged non-small-cell lung cancer progressing on crizotinib","volume":"21","author":"Lamberti","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/curroncol31080326","article-title":"Non-small-cell lung cancer patients harboring ROS1 rearrangement: Real world testing practices, characteristics and treatment patterns (ROS1REAL study)","volume":"31","author":"Janzic","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100838","DOI":"10.1016\/j.lanepe.2024.100838","article-title":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","volume":"38","author":"Timens","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): A phase II, prospective, multicenter, two-arms trial","volume":"25","author":"Landi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","article-title":"Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial","volume":"14","author":"Michels","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102237","DOI":"10.1016\/j.esmoop.2024.102237","article-title":"Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial","volume":"9","author":"Michels","year":"2024","journal-title":"ESMO Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107816","DOI":"10.1016\/j.lungcan.2024.107816","article-title":"Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: A systematic literature review and meta-analysis of real-world evidence","volume":"192","author":"Nadal","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wolf, J., Goring, S., Lee, A., Cho, B.C., Drilon, A., Yuan, Y., Ayers, D., Lozano-Ortega, G., Korol, E.E., and Korpach, S.G. (2025). Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC. Cancers, 17.","DOI":"10.3390\/cancers17050748"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bischoff, H., Gendarme, S., Somme, L., Chouaid, C., and Schott, R. (2025). Evolving therapeutic landscape of ROS1-positive non-small cell lung cancer: An updated review. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110626"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T05:28:42Z","timestamp":1772947722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["curroncol33030152"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33030152","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}